Interleukin-10 and Interleukin-12 Modulation in Patients with Relapsing-Remitting Multiple Sclerosis on Therapy with Interferon-beta 1a: Differences in Responders and Non Responders

We examined the effects of interferon (IFN)beta-1a on interleukin (IL)-12p70 and IL-10 secretion in 27 Relapsing Remitting Multiple Sclerosis (RRMS) patients, divided in responders and non-responders. In responders, IFNbeta-1a does not change the IL-12p70 concentrations, but it leads to a remarkable...

Full description

Saved in:
Bibliographic Details
Published in:Immunopharmacology and immunotoxicology 2008, Vol.30 (4), p.915-923
Main Authors: Carrieri, Pietro B., Ladogana, Paolo, Di Spigna, Gaetano, Fulvia de Leva, Maria, Petracca, Maria, Montella, Silvana, Buonavolontà, Luigi, Florio, Ciro, Postiglione, Loredana
Format: Article
Language:English
Subjects:
Adult
Biomarkers - blood
Cells, Cultured
Cytokines
Female
Follow-Up Studies
Humans
Interferon beta-1a
Interferon-Beta
Interferon-beta - administration & dosage
Interferon-beta - therapeutic use
Interleukin-10 - biosynthesis
Interleukin-12 - biosynthesis
Male
Middle Aged
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Multiple Sclerosis, Relapsing-Remitting - immunology
Multiple Sclerosis, Relapsing-Remitting - metabolism
Up-Regulation - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We examined the effects of interferon (IFN)beta-1a on interleukin (IL)-12p70 and IL-10 secretion in 27 Relapsing Remitting Multiple Sclerosis (RRMS) patients, divided in responders and non-responders. In responders, IFNbeta-1a does not change the IL-12p70 concentrations, but it leads to a remarkable increase in the IL-10 production. Besides, a high IL-10 IL-12 ratio is demonstrated during the first six months of therapy. In non-responders, there were not significant alterations in the cytokine profile. We suggest that IFNbeta-1a effect in RRMS patients could be explained by its modifying effect on cytokine pattern. Moreover, we propose a possible role of IL-10 IL-12 ratio as a serum marker predictive of favorable clinical course.
ISSN:0892-3973
1532-2513
DOI:10.1080/08923970802302753